U.S. Markets open in 4 hrs 2 mins
  • S&P Futures

    4,704.00
    +2.50 (+0.05%)
     
  • Dow Futures

    35,830.00
    +19.00 (+0.05%)
     
  • Nasdaq Futures

    16,494.75
    +13.50 (+0.08%)
     
  • Russell 2000 Futures

    2,365.40
    +1.20 (+0.05%)
     
  • Gold

    1,861.20
    -0.20 (-0.01%)
     
  • Silver

    24.88
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1369
    -0.0006 (-0.0568%)
     
  • 10-Yr Bond

    1.5890
    -0.0150 (-0.94%)
     
  • Vix

    17.59
    +0.48 (+2.81%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • USD/JPY

    114.3040
    +0.0520 (+0.0455%)
     
  • BTC-USD

    57,236.31
    +2,891.34 (+5.32%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • Nikkei 225

    29,683.09
    +84.43 (+0.29%)
     

SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against LifeMD, Inc. (LFMD) and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

PHILADELPHIA, April 24, 2021 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) on behalf of investors who purchased shares of the Company’s stock between January 19, 2021 and April 13, 2021, inclusive (the “Class Period”).

IMPORTANT DEADLINE: Investors who purchased LifeMD’s securities during the Class Period may, no later than June 15, 2021, seek to be appointed as a lead plaintiff representative in the action.

LifeMD investors who suffered an investment loss in excess of $250,000 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 – 1585, or by email at skaskela@kaskelalaw.com or online at https://kaskelalaw.com/case/lifemd-inc/, to discuss the opportunity to actively participate in the action as a lead plaintiff representative.

According to the complaint, on April 14, 2021, Culper Research issued a report alleging that “LifeMD appears to use unlicensed doctors to dispense OTC medications, has implemented an autoshipping/autobilling scheme, failed to honor guarantees, and put in place abusive telemarketing practices.” The Culper report also alleged that several of LifeMD’s executives were previously involved in “wide ranging fraud” at Redwood Scientific, which was charged by the U.S. Federal Trade Commission for “unlawful autoshipping, abusive telemarketing, and false claims.” According to the Culper report, “[a]t LifeMD, numerous customer reviews lead us to believe that the Company has implemented the same tactics. LifeMD touts its “recurring revenue” model yet we think much of the Company’s revenues are generated under false pretenses of ‘one-time purchases.’”

Following this news, shares of LifeMD’s common stock declined $2.84 per share, or nearly 25% in value, to close on April 14, 2021 at $9.00 per share, on heavy trading volume.

For additional information about this action and to discuss the opportunity to actively participate in the action as a lead plaintiff representative, LifeMD investors are encouraged to contact Kaskela Law LLC. Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

CONTACT:

D. Seamus Kaskela, Esq.
KASKELA LAW LLC
18 Campus Boulevard, Suite 100
Newtown Square, PA 19073
(484) 258 – 1585
(888) 715 – 1740
www.kaskelalaw.com
skaskela@kaskelalaw.com